Tvardi Therapeutics (NASDAQ:TVRD) Raised to “Sell” at Wall Street Zen

Tvardi Therapeutics (NASDAQ:TVRD) was upgraded by equities research analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report released on Saturday.

Several other equities research analysts have also commented on TVRD. Raymond James Financial upgraded shares of Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 target price on the stock in a research report on Wednesday, July 8th. BTIG Research reduced their price objective on shares of Tvardi Therapeutics to $5.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Piper Sandler raised shares of Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 price objective on the stock in a report on Wednesday, July 8th. UBS Group raised shares of Tvardi Therapeutics to an “outperform” rating and set a $10.00 price objective on the stock in a report on Wednesday, July 8th. Finally, HC Wainwright started coverage on shares of Tvardi Therapeutics in a research report on Monday, June 8th. They set a “buy” rating and a $9.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Tvardi Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Tvardi Therapeutics Price Performance

TVRD opened at $1.86 on Friday. The business has a 50 day simple moving average of $2.40 and a 200-day simple moving average of $3.10. The stock has a market capitalization of $24.81 million, a P/E ratio of -0.67 and a beta of 0.39. Tvardi Therapeutics has a 12 month low of $1.50 and a 12 month high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). Research analysts anticipate that Tvardi Therapeutics will post -2.35 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. acquired a new stake in Tvardi Therapeutics in the 2nd quarter valued at about $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Tvardi Therapeutics during the 2nd quarter valued at about $43,000. Headlands Technologies LLC acquired a new position in Tvardi Therapeutics during the second quarter worth about $80,000. New York State Common Retirement Fund acquired a new position in Tvardi Therapeutics during the second quarter worth about $92,000. Finally, Arax Advisory Partners raised its position in Tvardi Therapeutics by 277.2% during the fourth quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock worth $36,000 after acquiring an additional 6,173 shares during the last quarter. Institutional investors and hedge funds own 44.66% of the company’s stock.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.